The Diabetes Canada Clinical Practice Guidelines for the Prevention and Management of
Diabetes in Canada (CPG) were last published in 2018 (
1
). New evidence has been published since the 2018 guidelines, prompting this update
to our recommendations for Chapter 13, “Pharmacologic Glycemic Management of Type
2 Diabetes in Adults” (
1
).To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of DiabetesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diabetes Canada 2018 Clinical practice guidelines for the prevention and management of diabetes in Canada.Can J Diabetes. 2018; 42: S1-S325
- Diabetes Canada 2018 Clinical practice guidelines for the prevention and management of diabetes in Canada: Introduction.Can J Diabetes. 2018; 42: S1-S5
- Diabetes Canada 2018 Clinical practice guidelines for the prevention and management of diabetes in Canada.Methods. 2018; 42: S6-S9
- Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.N Engl J Med. 2015; 373: 2247-2257
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med. 2017; 377: 1228-1239
- Liraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2016; 375: 311-322
- Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med. 2016; 375: 1834-1844
- Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med. 2019; 381: 841-851
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial.Lancet. 2018; 392: P1519-P1529
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial.The Lancet. 2019; 394: 121-130
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.Lancet Diabetes Endocrinol. 2019; 7: 776-785
- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med. 2015; 373: 2117-2128
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME trial.Eur Heart J. 2016; 37: 1526-1534
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.N Engl J Med. 2016; 375: 323-334
- Canagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med. 2017; 377: 644-657
- Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med. 2019; 380: 2295-2306
- Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2019; 380: 347-357
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.The Lancet. 2019; 393: 31-39
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.N Engl J Med. 2019; 381: 1995-2008
- Alogliptin after acute coronary syndrome in patients with type 2 diabetes.N Engl J Med. 2013; 369: 1327-1335
- Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.N Engl JMed. 2013; 369: 1317-1326
- Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial.JAMA. 2019; 322: 1155-1166
- Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial.JAMA. 2019; 321: 69-79
- Association of glucose-lowering medications with cardiovascular outcomes: An umbrella review and evidence map.Lancet Diabetes Endocrinol. 2020; 8: 192-205
- Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update - the user's guide.Can J Diabetes. 2020; 44: 589-593
- Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis.Ann Intern Med. 2016; 164: 740-751
- Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: A network meta-analysis.PLoS ONE. 2015; 10e0125879
- The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.Diabetes Res Clin Pract. 2015; 109: 378-388
- Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.Clin Invest Med. 2016; 39: E48-E62
- Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.Diabetes Obes Metab. 2019; 20: 2255-2263
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.BMJ Open. 2012; 2e001007
- Efficacy and tolerability of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control: A randomized, double-blind, non-inferiority trial.Drugs Aging. 2015; 32: 469-476
- Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: A systematic review and meta-analysis.Eur J Clin Pharmacol. 2016; 72: 655-663
- The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: A systematic review and meta-analysis.Diabetes Metabolism Res Rev. 2014; 30: 11-22
- Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.J Diabetes. 2016; 9: 412-422
- Association of an intensive lifestyle intervention with remission of type 2 diabetes.JAMA. 2012; 308: 2489-2496
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet. 1998; 352: 837-853
- Early combination therapy for the treatment of type 2 diabetes mellitus: Systematic review and meta-analysis.Diabetes Obes Metab. 2014; 16: 410-417
- Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug naive type 2 diabetes.Diabetes Care. 2016; 39: 353-362
- Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: A systematic review of randomized controlled trials.Diabetes Obes Metab. 2014; 16: 179-185
- Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: A systematic review and meta-analysis.J Clin Med. 2019; 8: 45
- Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial.The Lancet. 2019; 394: 1519-1529
- Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.Diabetes Obes Metab. 2019; 21: 1128-1135
- Empagliflozin and progression of kidney disease in type 2 diabetes.N Engl J Med. 2016; 375: 323-334
- Updating insights into rosiglitazone and cardiovascular risk through shared data: Individual patient and summary level meta-analyses.BMJ. 2020; 368: l7078
- Association of glucose-lowering medications with cardiovascular outcomes: An umbrella review and evidence map.Lancet Diabetes Endocrinol. 2020; 8: 192-205
- Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: A network meta-analysis.Diabetes Obes Metab. 2012; 14: 810-820
- The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: Accumulated evidence from randomised controlled trial.Int J Clin Pract. 2016; 70: 132-141
- Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: A systematic review and mixed-treatment comparison meta-analysis.Open Med. 2012; 6: e62-e74
- Three-year efficacy of complex insulin regimens in type 2 diabetes.N Engl J Med. 2009; 361: 1736-1747
- Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long).Diabetes Care. 2012; 35: 2464-2471
- Efficacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis.CMAJ. 2009; 180: 385-397
- Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.Cochrane Database Syst Rev. 2007; CD005613
- Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: Ameta-analysis.Diabetes Res Clin Pract. 2008; 81: 184-189
- Systematic review and metaanalysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.Acta Diabetol. 2015; 52: 649-662
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials.Diabetes Obes Metab. 2013; 15: 175-184
- More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: The randomized head-to-head BRIGHT trial.Diabetes Care. 2018; 41: 2147-2154
- Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes. The SWITCH 2 Randomized Clinical Trial.JAMA. 2017; 318: 45-56
- Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.Diabetes Obes Metab. 2019; 21: 1634-1641
- Efficacy and safety of degludec versus glargine in type 2 diabetes.N Engl J Med. 2017; 377: 723-732
- Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial.Ann Intern Med. 2011; 154: 103-112
- Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: A randomized, placebo-controlled trial.Diabetes Obes Metab. 2015; 17: 1056-1064
- A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).Diabetes Obes Metab. 2014; 16: 636-644
- Prandial options to advance basal insulin glargine therapy: Testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: The GetGoal Duo-2 Trial.Diabetes Care. 2016; 39: 1318-1328
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: A systematic review and meta-analysis.Lancet. 2014; 384: 2228-2234
- Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Diabetes Care. 2017; 40: 614-624
- Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: Results of a meta-analysis.Postgraduate Medicine. 2017; 129: 436-445
- Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).Diabetes Obes Metab. 2017; 19: 1024-1031
- Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial.J Clin Endocrinol Metab. 2018; 103: 2291-2301
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): A randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.Lancet Diabetes Endocrinol. 2017; 5: 355-366
- Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: DUAL VII randomized clinical trial.Diabetes Care. 2018; 41: 1009-1016
- Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: A systematic review with indirect comparison meta-analysis.Diabetes Metab Res Rev. 2016; 33e2818
- Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.Diabetes Care. 2014; 37: 1815-1823
- Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years.Diabetes Obes Metab. 2014; 16: 124-136
- Efficacy and cardiovascular safety of linagliptin as an add-on to insulin in type 2 diabetes: A pooled comprehensive post hoc analysis.Can J Diabetes. 2016; 40: 50-57
- Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM).Endocrine Connections. 2017; 6: 748-757
- Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.Diabetes Obes Metab. 2019; 21: 2465-2473
- Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: A meta-analysis.Diabetes Obes Metab. 2009; 11: 53-59
- Faster aspart versus insulin sspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: The onset 2 trial.Diabetes Care. 2017; 40: 951-957
- Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): A randomised, treat-to-target clinical trial.Lancet Diabetes Endocrinol. 2014; 2: 30-37
- Diabetes Canada position statement on low-carbohydrate diets for adults with diabetes: A rapid review.Can J Diabetes. 2020; 44: 295-299
Article info
Identification
Copyright
© 2020 Canadian Diabetes Association.
